MedCity News
MARCH 14, 2023
Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.
Fierce Pharma
MARCH 16, 2023
AstraZeneca employees fight layoffs in India as drugmaker shifts 'strategic priorities' aliu Thu, 03/16/2023 - 09:54
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Medgadget
MARCH 17, 2023
Researchers at Linköping University in Sweden have developed a method whereby the body can ‘grow its own’ electrodes. The minimally invasive technique involves injecting a hydrogel that is laden with enzymes into target tissues. The enzymes interact with molecules that are present in the tissue to change the structure of the gel and allow it to become electrically conductive.
Pharmaceutical Technology
MARCH 14, 2023
The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years. Qdenga has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for four dengue virus serotypes and is designed to provide protection against any of these.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
MARCH 17, 2023
Without a new set of tools that clinicians can access at the point of care, the availability of information from QHINs will increase provider burdens because they will struggle to find the information needed to evaluate a patient, take action, complete documentation, and move to the next patient.
Fierce Pharma
MARCH 16, 2023
Novo Nordisk hit with two-year suspension from UK pharma group after online marketing breaches fkansteiner Thu, 03/16/2023 - 09:00
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
MARCH 17, 2023
Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health. Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved.
MedCity News
MARCH 16, 2023
Royalty Pharma’s milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy’s previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.
Fierce Pharma
MARCH 17, 2023
Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years aliu Fri, 03/17/2023 - 10:22
European Pharmaceutical Review
MARCH 17, 2023
In a first-of-its-kind commercial agreement, Great Ormond Street Hospital NHS Foundation Trust (GOSH) will work with Leucid Bio to manufacture LEU011, a lateral Chimeric Antigen Receptor (CAR) targeting NKG2D ligands. The CAR T therapy will be used in clinical studies for solid tumours and haematological malignancies. Under the agreement the parties will work together at state-of-the-art cleanroom facilities at the Zayed Centre for Research into Rare Disease in Children.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
MARCH 16, 2023
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge.
MedCity News
MARCH 15, 2023
Already, ChatGPT has been named as a co-author on at least four research papers. With proper management, AI generation could be an invaluable tool in clinical research—but only if we are mindful of the potential risks and biases that may arise from their usage and ensure transparency, fairness, and accountability in their use.
Fierce Pharma
MARCH 13, 2023
With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs' kdunleavy Mon, 03/13/2023 - 10:16
European Pharmaceutical Review
MARCH 15, 2023
New targeted drug revumenib facilitated complete response in around 40 percent of patients with acute leukaemia subtypes, according to data in a new pair of studies ( 1 ) and ( 2 ) published in Nature. The two genetic subtypes of acute leukaemia involved in this research are “driven by a rearrangement of the MLL1 gene or a mutation in the NPM1 gene.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Pharmaceutical Technology
MARCH 17, 2023
The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients. ADCs are designed for targeting cancer cells specifically and selectively provide a highly potent payload that may limit healthy cells’ damage.
MedCity News
MARCH 17, 2023
CMS should honor its commitment to Medicare beneficiaries, especially those who began home respiratory therapy under the PHE, without requiring them to “restart” the documentation process. Requiring requalification would also be a nightmare for physicians who are already overwhelmed with patient demands.
Fierce Pharma
MARCH 15, 2023
AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate kdunleavy Wed, 03/15/2023 - 10:09
Referral MD
MARCH 13, 2023
Photo by JoshuaWoroniecki on Pixabay Technology is everywhere these days, and that includes the realm of healthcare. You may have noticed this if you’ve visited the doctor or dentist recently. It’s so much easier to make appointments, view your medical records and even see a healthcare provider using technology. Here are a few ways that healthcare technology is transforming the medical industry.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Legacy MEDSearch
MARCH 15, 2023
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers.
MedCity News
MARCH 17, 2023
Perspectum — a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer — recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.
Fierce Pharma
MARCH 14, 2023
Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US kdunleavy Tue, 03/14/2023 - 10:56
European Pharmaceutical Review
MARCH 17, 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) ’s UK Stem Cell Bank is trialling an innovative new robot that grows stem cells. “The UK is only the second country where this technology has been tested” The MHRA’s UK Stem Cell Bank is testing the stem cell propagation robot over a 12-month period to see whether the cells produced by the fully automated Intelligent Cell Processing System meet the standards needed for them to be used in the manufacture of potentially life-savi
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Dominic Tyer
MARCH 11, 2023
Video of Dominic Tyer’s customer experience presentation to the Digital Pharma Show in December 2022
MedCity News
MARCH 13, 2023
AHIP and several other healthcare organizations launched the Connecting to Coverage Coalition last week in an effort to make the upcoming Medicaid redetermination process run smoothly. The coalition’s website includes studies on Medicaid redeterminations and frequently asked questions for enrollees. AHIP also released a report that shows 53.6% of those who will lose coverage will transition to employer-sponsored insurance and 21.2% will become uninsured.
Fierce Pharma
MARCH 17, 2023
Sanofi answers the call, joining Eli Lilly, Novo Nordisk in cutting insulin prices kdunleavy Fri, 03/17/2023 - 09:07
European Pharmaceutical Review
MARCH 17, 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for VYVGART ® (efgartigimod alfa-fcab). It is the first neonatal Fc receptor (FcRn) blocker to be approved in the UK for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. VYVGART is the first neonatal Fc receptor (FcRn) blocker to be approved in the UK for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
MARCH 16, 2023
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder. It will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodeg
MedCity News
MARCH 16, 2023
Some actions to reduce healthcare’s carbon footprint actually will save money, said Jonathan Perlin, CEO of the nonprofit national and international accrediting organization.
Fierce Pharma
MARCH 15, 2023
Pfizer adjusts EU vaccine deal but still wants payment for undelivered doses: FT esagonowsky Wed, 03/15/2023 - 08:43
Medgadget
MARCH 17, 2023
Researchers at Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland have developed a method to 3D print mineralized constructs with a little helping hand from bacteria. The technique consists of printing a polymer bioink that contains bacteria that will produce calcium carbonate when exposed to a urea solution. The two-step process also involves printing a construct and then exposing it to urea for several days, over which time the bacteria naturally mineralize the structure.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
98 
Let's personalize your content